Chromosome 8 open reading frame 33 (C8orf33)

Chromosome 8 open reading frame 33 (C8orf33, UPF0488 protein C8orf33) encodes a human protein of currently unknown molecular function but with emerging importance as a prognostic biomarker in cancers such as hepatocellular carcinoma and squamous cell carcinoma[1][2][6]. Its expression is differentially regulated across tissues, with upregulation in response to certain drugs and in some cancerous conditions. Predicted localization includes nucleus, mitochondrion, and peroxisomes[2]. Post-translational modifications are diverse, including phosphorylation, methylation, and acetylation. While its precise biological role remains undetermined, C8orf33 is incorporated into replication stress and tumor progression gene signatures and is used in molecular profiling for patient outcomes[1][2]. Interacting substances including methotrexate, vitamin E, cephaloridine, and carcinogen derivatives modify its expression but do not directly target it as a therapeutic receptor[2]. The collected evidence identifies C8orf33 as a protein-coding gene with diagnostic and prognostic implications in oncology, but not as an established therapeutic drug target or member of classical receptor/enzyme families.

Other names

UPF0488 protein C8orf33FLJ20989C8orf33LOC107983994RIKEN cDNA 1110038F14 gene1110038F14RikSimilar to human chromosome 8 open reading frame 33

Primarily through gene expression modulation following drug exposure rather than direct molecular targeting. Implied indirect modulation by chemotherapeutics or toxicants (e.g., cephaloridine and methotrexate elicit upregulation or altered function)